Peregrine Earnings Today: 3 Questions That Need Answers

Peregrine Pharmaceuticals (NASDAQ: PPHM  ) will report second quarter results after the bell today, and given that shares have done little this year, investors are right to be looking for clues as to when the company's promising immunotherapy drug for cancer may make an impact.

PPHM Chart

PPHM data by YCharts

In the following slideshow, I offer insight into Peregrine's bavituximab and outline key questions I'll be looking to have answered during the second quarter conference call.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 15, 2014, at 3:21 PM, TepperMay wrote:

    With Peregrine Being A Pivotal Stage Company, We View The Risk/Reward Profile As Favorable, Says Roth Capital

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3027934, ~/Articles/ArticleHandler.aspx, 4/1/2015 6:57:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...